{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG000","title":"Phase 1b/Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Phase 2 subjects includes all subjects who participated in Phase 1b","reportingStatus":"POSTED","timeFrame":"From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months","title":"Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD","type":"SECONDARY","unitOfMeasure":"Participants"}